CLINICAL RESEARCH
Triple Versus Dual Antiplatelet Therapy After Coronary Stenting
Impact on Stent Thrombosis
Seung-Whan Lee, MD,
Seong-Wook Park, MD, PhD, FACC*,
Myeong-Ki Hong, MD, PhD,
Young-Hak Kim, MD, PhD,
Bong-Ki Lee, MD,
Jong-Min Song, MD, PhD,
Ki Hoon Han, MD, PhD,
Cheol Whan Lee, MD, PhD,
Duk-Hyun Kang, MD, PhD,
Jae-Kwan Song, MD, PhD, FACC,
Jae-Joong Kim, MD, PhD and
Seung-Jung Park, MD, PhD, FACC
Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Manuscript received April 17, 2005;
revised manuscript received July 19, 2005,
accepted July 25, 2005.
* Reprint requests and correspondence: Dr. Seong-Wook Park, Department of Medicine, University of Ulsan, College of Medicine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul, 138-736, Korea (Email: swpark{at}amc.seoul.kr).
OBJECTIVES: We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or ticlopidine and cilostazol after coronary stenting.
BACKGROUND: Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in patients undergoing coronary stenting.
METHODS: Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy (aspirin plus clopidogrel or ticlopidine, group I, n = 1,597) and triple antiplatelet therapy (aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n = 1,415) groups. The primary end point included death, myocardial infarction, target lesion revascularization, or stent thrombosis within 30 days. The secondary end point was side effects of study drugs, including major bleeding, vascular complication, hepatic dysfunction, and hematological complications.
RESULTS: Multi-vessel stenting and the use of long stents were more prevalent in group II than in group I. The primary end point was 0.8% in group I and 0.3% in group II (p = 0.085). Stent thrombosis within 30 days was significantly lower in group II (n = 1, 0.1%) than in group I (n = 9, 0.5%; p = 0.024). The independent predictors of stent thrombosis were primary stenting (odds ratio [OR] 7.9, 95% confidence interval [CI] 2.0 to 30.8, p = 0.003) and triple therapy (OR 0.12, 95% CI 0.015 to 0.98, p = 0.048). The overall adverse drug effects, including major bleeding, neutropenia, and thrombocytopenia, were no different between two groups (1.8% vs. 2.6%, p = 0.104).
CONCLUSIONS: Compared with the dual antiplatelet regimen, triple antiplatelet therapy seemed to be more effective in preventing thrombotic complications after stenting without an increased risk of side effects. Triple antiplatelet therapy might be safely applied in patients or lesions with a high risk of stent thrombosis.
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | AMI = acute myocardial infarction | | CI = confidence interval | | MACE = major adverse cardiac event | | OR = odds ratio |
|
This article has been cited by other articles:
|
|
|
|
 
M. Ueno, J. L. Ferreiro, S. D. Tomasello, A. Tello-Montoliu, D. Capodanno, N. Seecheran, M. Kodali, K. Dharmashankar, B. Desai, R. K. Charlton, et al.
Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
J. Am. Coll. Cardiol. Intv.,
August 1, 2011;
4(8):
905 - 912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I.-S. Kim, Y.-H. Jeong, Y. Park, K.-S. Park, S.-E. Yun, J.-R. Park, S.-J. Hwang, E.-H. Koh, C. H. Kwak, J.-Y. Hwang, et al.
Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype
J. Am. Coll. Cardiol. Intv.,
April 1, 2011;
4(4):
381 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Kim, J.-Y. Lee, J.-M. Ahn, H. Song, W.-J. Kim, S.-C. Yun, D.-W. Park, S.-J. Kang, S.-W. Lee, C. Whan Lee, et al.
Impact of Bleeding on Subsequent Early and Late Mortality After Drug-Eluting Stent Implantation
J. Am. Coll. Cardiol. Intv.,
April 1, 2011;
4(4):
423 - 431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Ferreiro and D. J. Angiolillo
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
Circulation,
February 22, 2011;
123(7):
798 - 813.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-W. Suh, S.-P. Lee, K.-W. Park, H.-Y. Lee, H.-J. Kang, B.-K. Koo, Y.-S. Cho, T.-J. Youn, I.-H. Chae, D.-J. Choi, et al.
Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease: Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial
J. Am. Coll. Cardiol.,
January 18, 2011;
57(3):
280 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Ferreiro, A. R. Cequier, and D. J. Angiolillo
Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease
Diabetes and Vascular Disease Research,
October 1, 2010;
7(4):
274 - 288.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S.-J. Hwang, Y.-H. Jeong, I.-S. Kim, K.-S. Park, M.-K. Kang, J.-S. Koh, J. R. Park, Y. Park, E.-H. Koh, C. H. Kwak, et al.
Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. Desai and D. L. Bhatt
The State of Periprocedural Antiplatelet Therapy After Recent Trials
J. Am. Coll. Cardiol. Intv.,
June 1, 2010;
3(6):
571 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Croce
Antiplatelet Therapy After Percutaneous Coronary Intervention: Should Another Regimen Be "TAPT?"
Circ Cardiovasc Interv,
February 1, 2010;
3(1):
3 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ergelen, H. Uyarel, D. Osmonov, E. Ayhan, E. Akkaya, O. Soylu, A. L. Orhan, N. Sayar, M. Bozbay, A. Turer, et al.
Early Stent Thrombosis in Patients Undergoing Primary Coronary Stenting for Acute Myocardial Infarction: Incidence, a Simple Risk Score, and Prognosis
Clinical and Applied Thrombosis/Hemostasis,
February 1, 2010;
16(1):
33 - 41.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Montalescot, D. Brieger, K. A. Eagle, F. A. Anderson Jr, G. FitzGerald, M. S. Lee, Ph. G. Steg, A. Avezum, S. G. Goodman, J. M. Gore, et al.
Unprotected left main revascularization in patients with acute coronary syndromes
Eur. Heart J.,
October 1, 2009;
30(19):
2308 - 2317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis
Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
J. Am. Coll. Cardiol. Intv.,
July 1, 2009;
2(7):
583 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-Y. Chen, S.-W. Rha, Y.-J. Li, K. L. Poddar, Z. Jin, Y. Minami, L. Wang, E. J. Kim, C. G. Park, H. S. Seo, et al.
Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Circulation,
June 30, 2009;
119(25):
3207 - 3214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Prasad and D. R Holmes
Update on dual antiplatelet therapy for percutaneous coronary intervention
Heart,
June 1, 2009;
95(11):
861 - 865.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1101 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. Park and Y.-H. Kim
Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia
Circulation,
December 16, 2008;
118(25):
2730 - 2737.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Chhatriwalla and D. L. Bhatt
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
217 - 225.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, et al.
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
Eur. Heart J.,
September 2, 2008;
29(18):
2202 - 2211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Chesebro
Diabetic atherothrombosis: helpful adjunctive therapy
Eur. Heart J.,
September 2, 2008;
29(18):
2191 - 2192.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Blanc, J. Almendral, M. Brignole, M. Fatemi, K. Gjesdal, E. Gonzalez-Torrecilla, P. Kulakowski, G. Y.H. Lip, D. Shah, C. Wolpert, et al.
Consensus document on antithrombotic therapy in the setting of electrophysiological procedures
Europace,
May 1, 2008;
10(5):
513 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker and B. Meier
Late Coronary Stent Thrombosis
Circulation,
October 23, 2007;
116(17):
1952 - 1965.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, D. J. Kereiakes, W. K. Laskey, A. Colombo, S. G. Ellis, T. D. Henry, J. J. Popma, P. W.J.C. Serruys, T. Kimura, D. O. Williams, et al.
Thrombosis and Drug-Eluting Stents: An Objective Appraisal
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
109 - 118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Moliterno and C. L. Campbell
Unraveling Questions Surrounding Clopidogrel Resistance and Stent Thrombosis: One Less Snag
J. Am. Coll. Cardiol.,
June 19, 2007;
49(24):
2318 - 2319.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Buonamici, R. Marcucci, A. Migliorini, G. F. Gensini, A. Santini, R. Paniccia, G. Moschi, A. M. Gori, R. Abbate, and D. Antoniucci
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
J. Am. Coll. Cardiol.,
June 19, 2007;
49(24):
2312 - 2317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Topakian, K. Nussbaumer, J. Trenkler, F. T. Aichner, J.-H. Buhk, A. Wellmer, and M. Knauth
Late in-stent thrombosis following carotid angioplasty and stenting
Neurology,
January 30, 2007;
68(5):
392 - 393.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.-Y. Brichon, P. Boitet, A. Dujon, J. Mouroux, C. Peillon, M. Riquet, J.-F. Velly, and H.-B. Ris
Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting
Eur J Cardiothorac Surg,
November 1, 2006;
30(5):
793 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1689 - 1706.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Post-Stenting Antiplatelet Therapy: Further Insights
Journal Watch Cardiology,
December 16, 2005;
2005(1216):
4 - 4.
[Full Text]
|
|
|
|
